<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02748135</url>
  </required_header>
  <id_info>
    <org_study_id>ONC-403-001</org_study_id>
    <nct_id>NCT02748135</nct_id>
  </id_info>
  <brief_title>A Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma</brief_title>
  <official_title>A Phase 1, Open-Label, Multicenter, Dose Escalation Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma, Neuroblastoma, Ewing Sarcoma or Alveolar Rhabdomyosarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oncurious NV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beat Childhood Cancer</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oncurious NV</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and tolerability profile of TB-403&#xD;
      (humanized monoclonal antibody against placental growth factor (PlGF)) in pediatric subjects&#xD;
      with relapsed or refractory Medulloblastoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The maximum tolerated dose of TB-403 will be determined in pediatric subjects with relapsed&#xD;
      or refractory Medulloblastoma (MB) and as well Neuroblastoma (NB), Ewing Sarcoma (ES) and&#xD;
      Alveolar Rhabdomyosarcoma (ARMS).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Actual">October 6, 2020</completion_date>
  <primary_completion_date type="Actual">October 6, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary safety endpoint will be the determination of the maximum tolerated dose (MTD) / study maximum dose (SMD) based on the occurrence of dose-limiting toxicities (DLTs) during the 28-day DLT assessment period.</measure>
    <time_frame>Day28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>TB-403 total exposure (AUC∞) after single ascending dose</measure>
    <time_frame>Day 1, day 4, day 8, day 15, day 29, day 60, day 90, day 165 and day 195.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TB-403 Dose/CL after single ascending dose</measure>
    <time_frame>Day 1, day 4, day 8, day 15, day 29, day 60, day 90, day 165 and day 195.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TB-403 Volume of the central compartment (Vc) after single ascending dose</measure>
    <time_frame>Day 1, day 4, day 8, day 15, day 29, day 60, day 90, day 165 and day 195.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TB-403 Volume of distribution at steady-state (Vss) after single ascending dose</measure>
    <time_frame>Day 1, day 4, day 8, day 15, day 29, day 60, day 90, day 165 and day 195.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TB-403 terminal half-life (t½,z) after single ascending dose</measure>
    <time_frame>Day 1, day 4, day 8, day 15, day 29, day 60, day 90, day 165 and day 195.</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Relapsed or Refractory Medulloblastoma (MB), Neuroblastoma (NB), Ewing Sarcoma (ES) and Alveolar Rhabdomyosarcoma (ARMS)</condition>
  <arm_group>
    <arm_group_label>TB-403 20mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TB-403 50mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TB-403 100mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TB-403 175mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TB-403 20mg/kg</intervention_name>
    <description>bi-weekly intravenous doses of TB-403 20mg/kg</description>
    <arm_group_label>TB-403 20mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TB-403 50mg/kg</intervention_name>
    <description>bi-weekly intravenous doses of TB-403 50mg/kg</description>
    <arm_group_label>TB-403 50mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TB-403 100mg/kg</intervention_name>
    <description>bi-weekly intravenous doses of TB-403 100mg/kg</description>
    <arm_group_label>TB-403 100mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TB-403 175mg/kg</intervention_name>
    <description>bi-weekly intravenous doses of TB-403 175mg/kg</description>
    <arm_group_label>TB-403 175mg/kg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provide written informed consent (Subject or legal representative)&#xD;
&#xD;
          2. Be &gt; 6 months and &lt; 18 years of age. For each dose cohort, the first 3 subjects must&#xD;
             be at least 2 years of age&#xD;
&#xD;
          3. Have a histologically-confirmed diagnosis of MB, NB, ES, or ARMS&#xD;
&#xD;
          4. Have documented relapse or refractoriness after standard-of-care therapy&#xD;
&#xD;
          5. Have undergone magnetic resonance imaging (MRI) for MB (brain [all cohorts] and spinal&#xD;
             cord [cohort 4 only], a computerized tomography (CT) / metaiodobenzylguanidine (MIBG)&#xD;
             scan for NB, and CT / magnetic resonance imaging (MRI) for ES or ARMS within 1 month&#xD;
             prior to first dose of study treatment&#xD;
&#xD;
          6. Have a Lansky score ≥ 40 for subjects up to 16 years of age or a Karnofsky score ≥ 40&#xD;
             for subjects 16 years of age to &lt; 18 years&#xD;
&#xD;
          7. Have adequate organ function, defined as:&#xD;
&#xD;
               -  Peripheral absolute neutrophil count ≥ 1.5 × 10^9/L&#xD;
&#xD;
               -  Platelet count ≥ 100 × 10^9/L (transfusion to reach this level is permitted)&#xD;
&#xD;
               -  Hemoglobin ≥ 8mg/dL (transfusion to reach this level is permitted)&#xD;
&#xD;
               -  International normalized ratio (INR) &lt; 1.5; partial thromboplastin time (PTT) &lt;&#xD;
                  1.5 upper limit of normal (ULN)&#xD;
&#xD;
               -  Creatinine clearance &gt; 50mL/min/1.73m2 or serum creatinine ≤ specified maximum&#xD;
                  values based on age, as described below:&#xD;
&#xD;
               -  6 months to 3 years of age: serum creatinine ≤ 0.4mg/dL&#xD;
&#xD;
               -  3 to 13 years of age: serum creatinine ≤ 0.7mg/dL&#xD;
&#xD;
               -  &gt; 13 years of age: serum creatinine ≤ 1mg/dL&#xD;
&#xD;
               -  Serum aspartate aminotransferase (AST) and serum alanine aminotransferase (ALT) &lt;&#xD;
                  2.5 × ULN; serum bilirubin &lt; 1.5 × ULN&#xD;
&#xD;
          8. Have no symptoms of cranial hypertension or convulsions within 14 days before Cycle 1&#xD;
             Day 1 (anti-epileptic drugs and corticoids are allowed to control any preexisting&#xD;
             symptoms)&#xD;
&#xD;
          9. If female of child bearing potential, must not be lactating and must have a negative&#xD;
             pregnancy test (blood or urine, at the discretion of the investigator) prior to&#xD;
             enrollment and use effective contraception during study participation. Women should&#xD;
             continue effective contraception for 3 months following last dose of TB-403.&#xD;
&#xD;
         10. If a sexually-active male, must agree to use a latex condom during any sexual contact&#xD;
             with females of child bearing potential while participating in the study and for 3&#xD;
             months following last dose of TB-403.&#xD;
&#xD;
         11. For subjects on corticosteroids for endocrine deficiencies or tumor-associated&#xD;
             symptoms, must be on a stable (or decreasing) dose for at least 7 days before first&#xD;
             dose of study treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have any clinically significant disease considered by the investigator to interfere&#xD;
             with study participation&#xD;
&#xD;
          2. Have not fully recovered from the acute toxic effects of prior anticancer therapy&#xD;
             (e.g., chemotherapy, immunotherapy, radiation therapy) or are currently receiving&#xD;
             cytotoxic chemotherapy, immunotherapy or radiation therapy. Subjects must be within&#xD;
             the following timelines relative to first dose of study treatment:&#xD;
&#xD;
               -  Myelosuppressive chemotherapy: Must not have received within 2 weeks (6 weeks if&#xD;
                  prior nitrosourea)&#xD;
&#xD;
               -  Hematopoietic growth factors: At least 5 days since the completion of therapy&#xD;
                  with a growth factor&#xD;
&#xD;
               -  Biologic (anti-neoplastic agent): At least 7 days since the completion of therapy&#xD;
                  with a biologic agent. For agents that have known adverse events occurring beyond&#xD;
                  7 days after administration, this period must be extended beyond the time during&#xD;
                  which adverse events are known to occur. The duration of this interval must be&#xD;
                  discussed with the Sponsor&#xD;
&#xD;
               -  Immunotherapy: At least 6 weeks since the completion of any type of&#xD;
                  immunotherapy, e.g., tumor vaccines&#xD;
&#xD;
               -  Monoclonal antibodies: At least 7 days or 3 half-lives, whichever is longer, must&#xD;
                  have elapsed since prior treatment with a monoclonal antibody&#xD;
&#xD;
               -  Radiotherapy: At least 14 days since the last treatment except for radiation&#xD;
                  delivered with palliative intent to a non-target site&#xD;
&#xD;
               -  Stem Cell Transplant or Rescue: No evidence of active graft vs. host disease and&#xD;
                  ≥ 2 months must have elapsed since transplant&#xD;
&#xD;
          3. Have participated in another therapeutic clinical trial with an investigational drug&#xD;
             within 1 month before first dose of study treatment&#xD;
&#xD;
          4. Have any known active uncontrolled infection&#xD;
&#xD;
          5. Have had major surgery or bone fracture within 28 days before first dose of study&#xD;
             treatment&#xD;
&#xD;
          6. Have previously received TB-403&#xD;
&#xD;
          7. Have a history of severe allergic or anaphylactic reactions or hypersensitivity to&#xD;
             recombinant proteins or excipients in the investigational drug&#xD;
&#xD;
          8. Are receiving increasing doses of corticosteroids&#xD;
&#xD;
          9. Are eligible for a curative treatment option&#xD;
&#xD;
         10. Have had a prior thrombotic event (e.g., pulmonary embolism, deep vein thrombosis) or&#xD;
             are currently receiving therapeutic or prophylactic doses of anticoagulants.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.oncurious.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>April 8, 2016</study_first_submitted>
  <study_first_submitted_qc>April 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2016</study_first_posted>
  <last_update_submitted>January 11, 2021</last_update_submitted>
  <last_update_submitted_qc>January 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Neuroblastoma</mesh_term>
    <mesh_term>Rhabdomyosarcoma</mesh_term>
    <mesh_term>Sarcoma, Ewing</mesh_term>
    <mesh_term>Medulloblastoma</mesh_term>
    <mesh_term>Rhabdomyosarcoma, Alveolar</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

